$QNTM

Quantum BioPharma (QNTM) signed a study start-up agreement with Thermo Fisher Scientific for its Phase 2 Lucid-MS trial for multiple sclerosis, following FDA clearance. The trial will evaluate efficacy, safety, and tolerability. MS affects 2.8 million people globally, with the therapeutic market projected to exceed $38B by 2030, according to the company.

Quantum BioPharma (QNTM) announced that the U.S. District Court for the Southern District of New York consolidated its lawsuit and a class action against CIBC and RBC, alleging stock manipulation. The court appointed Grant & Eisenhofer as lead counsel. The lawsuit claims defendants used 'spoofing' techniques to manipulate Quantum's stock price between 2020 and 2024, harming shareholders.

Quantum BioPharma (QNTM) has signed a contract with Thermo Fisher Scientific to implement its Phase 2 clinical trial for Lucid-MS, a treatment for multiple sclerosis. The trial will evaluate the drug's efficacy, safety, and tolerability. Quantum BioPharma received FDA clearance to proceed with the study. The multiple sclerosis market is projected to exceed $38 billion by 2030, according to Grand View Research.

Quantum BioPharma (QNTM) is advancing Lucid-MS into Phase 2 trials for multiple sclerosis, with co-founder Anthony Durkacz highlighting the potential. The company also owns 20% of Unbuzzd Wellness, earning a 7% royalty on sales until $250 million, then 3% thereafter. Lucid-MS targets myelin degradation, while Unbuzzd addresses alcohol misuse.

Quantum BioPharma (NASDAQ: QBIO) is advancing its multiple sclerosis drug candidate, Lucid-MS, to Phase 2 trials after FDA clearance. Lucid-MS targets myelin breakdown, a key factor in MS, and differs from existing treatments that primarily modify immune response. Preclinical studies showed promise, but human efficacy remains unproven. The global MS therapeutics market is projected to reach $34.8 billion by 2025, according to Precedence Research.

Quantum BioPharma (QNTM) received FDA approval to advance Lucid-MS into phase 2 trials. The company's MS treatment showed a favorable safety profile in phase 1. This approval allows patient recruitment and clinical testing to begin.

Quantum BioPharma (QNTM) received a Buy rating and $8 price target from Rodman & Renshaw, more than double its current share price. The rating is based on LUCID-MS, an experimental oral therapy for progressive multiple sclerosis, which targets the PAD2 enzyme. The FDA cleared the drug for a Phase 2 trial, with enrollment expected to begin in 2027 and results projected for 2029. The company has $9.5 million in cash but may need to raise additional capital for the trial. Quantum also holds a 19.5%

Rodman & Renshaw initiated coverage on Quantum BioPharma (QNTM) with a BUY rating and a $8 price target. The research report was unpaid, with no fees from Quantum BioPharma. Quantum BioPharma focuses on biotech solutions for neurodegenerative and metabolic disorders.

Quantum BioPharma (QNTM) received FDA clearance for a phase 2 trial of Lucid-MS, a novel MS treatment targeting demyelination. The trial is historic as it tests a new mechanism never before used in MS patients. The company aims to shield and potentially rebuild the myelin sheath, addressing a significant unmet medical need. Analysts have given the company a fresh buy rating. The global MS therapeutics market is projected to reach $38.62 billion by 2030.

Opus Genetics (IRD) rose 27% after positive clinical trial data. Quantum (QNTM) gained 10% with FDA Phase 2 trial clearance. Pulse Biosciences (PLSE) surged 15% without specific news. Decoy Therapeutics (DCOY) and ONWARD Medical (ONWD.BR) also traded higher on updates.